
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1015 | 1015 | 1013 | 1012 | 1565 | 1882 |
Fund Return | 1.54% | 1.54% | 1.34% | 0.4% | 9.36% | 6.53% |
Place in category | 54 | 54 | 50 | 40 | 27 | 9 |
% in Category | 38 | 38 | 40 | 28 | 33 | 14 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
T. Rowe Price Capital Appreciation | 33.46B | -0.03 | 6.70 | 10.19 | ||
T. Rowe Price Capital AppreciationI | 28.17B | 0.00 | 6.83 | - | ||
T. Rowe Price Blue Chip Growth | 27.36B | -9.15 | 8.87 | 13.14 | ||
T. Rowe Price Blue Chip Growth I | 25.39B | -9.11 | 9.01 | - | ||
T. Rowe Price Instl Large Cap Growt | 19.39B | -7.89 | 9.64 | 14.57 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
MFS International New Discovery R6 | 4.74B | 2.55 | 2.24 | 4.94 | ||
Fidelity Series International Sm C | 3.78B | 3.02 | 4.01 | 7.20 | ||
T. Rowe Price International Discove | 3.29B | 1.59 | 0.57 | - | ||
Artisan International Small Cap Ins | 2.75B | -1.38 | -1.44 | - | ||
Oppenheimer International Small-MiI | 1.8B | 2.73 | -3.18 | 6.25 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
BAWAG | AT0000BAWAG2 | 2.57 | 88.550 | +2.02% | |
MercadoLibre | US58733R1023 | 2.19 | 2,109.23 | +3.54% | |
Spie | FR0012757854 | 1.60 | 39.98 | +2.30% | |
Redcare Pharmacy NV | NL0012044747 | 1.56 | 128.300 | +0.79% | |
Amplifon | IT0004056880 | 1.19 | 16.750 | -4.61% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Strong Sell |
Technical Indicators | Sell | Strong Sell | Strong Sell |
Summary | Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review